The FDA issued a complete response letter to Corcept Therapeutics for relacorilant in patients with hypertension secondary to hypercortisolism (Cushing syndrome), requesting additional efficacy evidence and derailing hopes for a 2026 launch in that indication. Corcept disclosed the CRL publicly and signaled it will meet with regulators to define next steps. The company is now redirecting focus to a separate approval path: relacorilant’s potential use in platinum-resistant ovarian cancer, with a July 2026 PDUFA date remaining in play.